Clinicopathological features of metaplastic breast carcinoma

Hasdemir, Oğuz; Tokgöz, Serhat; Köybaşıoğlu, Fulya; Karabacak, Harun; Yücesoy, Cüneyt; Imamoğlu, Gökşen İnanç

doi:10.17219/acem/68293

Cited by 11 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic implications of these findings are currently unknown. Similarly, other studies have also reported the occurrence of these histologic findings as seen in our study, 9,26 with unclear prognostic implications.…”

Section: Treatment and Outcomesupporting

confidence: 81%

See 1 more Smart Citation

Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma

Abada

Daaboul

Ebare

et al. 2021

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Metaplastic breast carcinoma is an aggressive form of breast cancer that accounts for 0.5% to 3% of all breast cancers. Objective.— To study the clinicopathologic characteristics and outcomes of this rare disease. Design.— Retrospective study of patients with a diagnosis of metaplastic breast carcinoma between 2000 and 2019. Hematoxylin-eosin–stained slides were reviewed and additional clinical data were obtained from electronic medical records. Univariable and multivariable Cox proportional hazard regression analyses were used to determine associations between overall survival and several clinicopathologic variables. Results.— Of the 125 patients with metaplastic breast carcinoma identified, only patients with high-grade disease (N = 115) were included in the data analysis. A total of 38 participants (33%) were white, 66 (57%) were African American, and 11 (10%) belonged to other ethnicities. The median age at diagnosis was 57 years. The median tumor size was 3 cm. Heterologous histology was seen in 30% of cases. Multivariable analyses showed that patients with a larger tumor size had worse overall survival (hazard ratio [HR], 1.25; 95% CI, 1.10–1.44; P < .001). Distant metastatic disease was also associated with worse overall survival on multivariable analysis (HR, 10.27; 95% CI, 2.03–55.54; P = .005). In addition to treatment with either partial or complete mastectomies, 84 patients (73%) received chemotherapy. Multivariable analyses showed that chemotherapy had no effect on overall survival (HR, 0.53; 95% CI, 0.09–6.05; P = .55). Conclusions.— A larger tumor size and distant metastatic disease are associated with worse overall survival in patients with metaplastic breast carcinoma. Additional studies are needed to further characterize our findings.

show abstract

Section: Treatment and Outcomesupporting

confidence: 81%

“…1 In more than 90% of MBCs, CK5/6, CK14, and EGFR expressions are positive, whereas ER, PR, and HER2 are negative immunohistochemically. 9 Immunohistology panels with CAM5.2, AE1/AE3, CK7, CK5, CK14, and CK17 will demonstrate at least 1 keratin-positive profile. 3 In the absence of any keratin, another diagnosis should be entertained.…”

mentioning

confidence: 99%

Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma

Abada

Daaboul

Ebare

et al. 2021

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Constituting < 1% of all invasive breast cancers, metaplastic breast cancer (MBC) is a seldom encountered malignancy [ 1 , 2 ]. The term “metaplastic carcinoma” was first described by Huvos and colleagues in 1973 [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathologic Features of Metaplastic Breast Carcinoma: Experience From a Tertiary Cancer Center of North India

Damera¹,

Chowdhury²,

Tripathi³

et al. 2022

Cureus

View full text Add to dashboard Cite

IntroductionMetaplastic breast cancer (MBC) is a rare malignancy that accounts for < 1% of all breast cancers. The aim of this study is to evaluate the clinicopathologic characteristics of MBC patients treated at a tertiary cancer center. Materials and methodsIn this study, the authors retrospectively analyzed the prospectively maintained data of MBC patients treated at a tertiary cancer care center in North India between January 2019 and July 2022. ResultsA total of 28 MBCs were identified. The median age of presentation was 47 years (range 27-81 years). Seventeen patients (60.7%) presented with clinical T3/T4 disease, and axillary nodal involvement was detected in 11 patients (39.3%) at presentation. Two patients had metastatic disease at presentation. A preoperative diagnosis of MBC on core biopsy was attained in five patients (17.9%), and the most common histologic subtype was sarcomatoid carcinoma. Triple-negative receptor status was observed in 15 patients (53.6%). Six patients (21.4%) underwent upfront breast conservation surgery and another six (21.4%) upfront mastectomy. Thirteen patients (46.4%) underwent mastectomy following neoadjuvant therapy. Definitive axillary nodal metastasis was found in eight patients (32%). Following neoadjuvant chemotherapy, five patients (35.7%) had stable disease, disease progression was evident in five patients (35.7%), partial response in four patients (28.6%), and no patient evinced complete response. Adjuvant postoperative radiation therapy was administered in 16 patients (57.1%). At a median follow-up of 13.2 months (range 4-26 months), 16 patients (57.1%) were alive with no evidence of disease, one patient (3.6%) was alive with disease, nine patients (32.1%) died of disease, and two patients (7.2%) died of other causes. One patient suffered from locoregional recurrence and nine patients developed distant metastasis. ConclusionMBC is an infrequent entity among breast carcinomas in India, which is similar to the reports of MBC worldwide. The diagnosis of MBC is difficult and requires the use of immunohistochemistry. Most of the cases in our study presented with a larger tumor size; however, they displayed a relatively lower incidence of nodal involvement as well as hormone receptor negativity. Being a rare and heterogeneous disease, largescale studies are essential for better understanding and management of these tumors.

show abstract

“…Metaplastic breast cancer (MBC) is a very rare type of invasive breast cancer in which the original cell type, usually glandular epithelium, differentiates into either epithelial and/or mesenchymal cell types with glandular and nonglandular components [1,2]. According to the World Health Organization (WHO), MBC includes several subtypes, including low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, squamous cell carcinoma, spindle cell carcinoma, mixed metaplastic carcinoma, myoepithelial carcinoma, and metaplastic carcinoma with mesenchymal differentiation-notably chondroid, osseous, and other types of mesenchymal differentiation [3].…”

Section: Introductionmentioning

confidence: 99%

Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

et al. 2020

View full text Add to dashboard Cite

Background: Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear. Methods: We compared the clinical outcomes between women with metaplastic breast cancer and women with triple-negative breast cancer diagnosed between 1994 and 2014. Metaplastic breast cancer patients were matched 1:3 to triple-negative breast cancer patients by stage and age at diagnosis. Distant disease-free survival (DDFS) and overall survival (OS) were estimated using Kaplan Meier methods and Cox proportional hazard regression models. Immune checkpoint markers were characterized by immunohistochemistry in a subset of samples.Results: Forty-four metaplastic breast cancer patients (stage I 14%; stage II 73%; stage III 11%; stage IV 2%) with an average age of 55.4 (± 13.9) years at diagnosis. Median follow-up for the included metaplastic breast cancer and triple-negative breast cancer patients (n = 174) was 2.8 (0.1-19.0) years. The DDFS and OS between matched metaplastic breast cancer and triple-negative breast cancer patients were similar, even when adjusting for clinical covariates (DDFS: HR = 1.64, p = 0.22; OS: HR = 1.64, p = 0.26). Metaplastic breast cancer samples (n = 27) demonstrated greater amount of CD163 in the stroma (p = 0.05) and PD-L1 in the tumor (p = 0.01) than triplenegative breast cancer samples (n = 119), although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples (p = 0.02). Conclusions:Patients with metaplastic breast cancer had similar outcomes to those with triple-negative breast cancer based on DDFS and OS. The immune checkpoint marker profile of metaplastic breast cancers in this study may prove useful in future studies attempting to demonstrate an association between immune profile and survival.

show abstract

Clinicopathological features of metaplastic breast carcinoma

Cited by 11 publications

References 19 publications

Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma

Clinicopathologic Characteristics and Outcome Descriptors of Metaplastic Breast Carcinoma

Clinicopathologic Features of Metaplastic Breast Carcinoma: Experience From a Tertiary Cancer Center of North India

Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

Contact Info

Product

Resources

About